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Normas Clínicas
Clinical Guidelines
Resumo
A Sociedade Portuguesa de Reumatologia e a Sociedade 
Portuguesa de Pneumologia actualizaram as recomenda-
ções para o diagnóstico e a terapêutica das tuberculoses 
latente (TL) e activa (TD) em doentes com doenças infla-
matórias articulares (DIA), candidatos a tratamento com 
antagonistas do factor de necrose tumoral alfa (TNFα). 
Com o objectivo de reduzir o risco de reactivação da tu-
berculose (TB) ou nova infecção, recomenda -se o rastreio 
de TD e TL tão precocemente quanto possível, preferen-
cialmente no momento do diagnóstico da DIA, e repetir 
a avaliação do doente antes de iníciar terapêutica anti-
-TNFα. O tratamento da TD e TL deve ser sempre su-
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The Portuguese Society of Rheumatology and the Por-
tuguese Society of Pulmonology have updated the 
guidelines for the diagnosis and treatment of latent tu-
berculosis infection (LTBI) and active tuberculosis 
(ATB) in patients with inflammatory joint diseases 
(IJD) that are candidates to therapy with tumour necro-
sis factor alpha (TNFα) antagonists. In order to reduce 
the risk of tuberculosis (TB) reactivation and the inci-
dence of new infections, TB screening is recommended 
to be done as soon as possible, ideally at the moment of 
IJD diagnosis, and patient assessment repeated before 
starting anti -TNFα therapy. Treatment for ATB and 
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pervisionado por um especialista em TB. Quando hou-
ver indicação para terapêutica de TB, esta deverá ser 
cumprida integralmente antes de se iniciar o anti -TNFα. 
No caso da actividade da DIA o exigir, o anti -TNFα 
poderá ser iniciado após dois meses de terapêutica antiba-
cilar, no caso de TD, ou após um mês, no caso de TL. 
Todos os doentes devem realizar radiografia do tórax. 
Alterações compatíveis com complexo de Gohn de-
vem ser tratadas como TL. Lesões residuais obrigam a 
excluir TB activa. Se se suspeitar de lesões em activi-
dade, o diagnóstico de TD deve ser excluido e o tra-
tamento adequado instituído. 
A prova tuberculínica (PT), com 2 unidades de tubercu-
lina RT23, deverá ser efectuada em todos os doentes. Se 
a induração for <5 mm, a prova deve ser repetida dentro 
de 1 a 2 semanas no antebraço oposto, e considerada 
negativa apenas se o segundo resultado for igualmente <5 
mm. As PT positivas obrigam a tratamento de TL, ex-
cepto se o doente tiver sido previamente tratado de forma 
adequada. Se a PT é realizada apenas em fase de imuno-
depressão, mesmo que seja negativa, deve ser equaciona-
do o tratamento de TL antes de iniciar terapêutica anti-
-TNFα, após ponderar a relação risco/benefício.
Rev Port Pneumol 2007; XIV (2): 271-283
Palavras -chave: Guidelines, Sociedade Portuguesa 
de Reumatologia, Sociedade Portuguesa de Pneumo-
logia, tuberculose, anti -TNFα.
LTBI must be done under the care of a TB specialist. 
When TB treatment is indicated, it should be complet-
ed prior to starting anti -TNFα therapy. If the IJD ac-
tivity justifies the need for immediate treatment, anti-
-TNFα therapy can be started two months after 
antituberculous therapy has been initiated, in the case 
of ATB, and one month after in the case of LTBI. Chest 
X -ray is mandatory for all patients. If Gohn’s complex 
is present, the patient should be treated for LTBI; healed 
lesions require the exclusion of ATB. In cases of sus-
pected active lesions, ATB should be excluded/con-
firmed and adequate therapy initiated. 
Tuberculin skin test, with two units of RT23, should 
be performed in all patients. If the induration is <5 
mm, the test should be repeated within 1 to 2 weeks, 
on the opposite forearm, and will be considered nega-
tive only if the result is again <5 mm. Positive TST 
implicates LTBI treatment, unless previous proper 
treatment was provided. If TST is performed in im-
munossuppressed IJD patients, LTBI treatment 
should be offered to the patient before starting anti-
-TNF -α therapy, even in the presence of a negative 
test, after risk / benefit assessment.
Rev Port Pneumol 2007; XIV (2): 271-283
Key-words: Guidelines, Portuguese Society of Rheu-
matology, Portuguese Society of Pulmonology, Tu-
berculosis, Anti -TNFα drugs.
Introduction
Tumor necrosis factor alpha (TNF -α) in-
hibitors are used to treat inflammatory joint 
diseases (IJD) such as rheumatoid arthritis 
(RA), psoriatic arthritis (PsA) and ankylos-
ing spondylitis (AS). In populations with a 
high incidence of tuberculosis (TB), there 
have been an increased number of TB cases 
reported in patients undergoing these thera-
pies.1 In fact, the relative risk (RR) of devel-
oping TB is 19 times higher in RA patients 
under anti -TNF -α therapy than in RA pa-
tients not undergoing such therapy.1 How-
ever, it is important to point out that RA 
patients treated with conventional immu-
nosuppressive drugs have a RR for TB that 
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is 4 times higher than in the general popula-
tion.1
In patients treated with anti -TNF -α drugs, 
ATB usually results from the reactivation of 
a latent infection. TB onset usually occurs 
during the first months of treatment and of-
ten presents an atypical behavior, which 
may pose difficulties to the diagnosis.2 In 
countries with high incidence of TB, cases 
caused by new infections are particularly 
frequent. TNF -α is fundamental for the 
immunological defence against Mycobacte-
rium tuberculosis, specially in the formation 
and maintenance of granulomas. Animal 
models show that it is possible to reactivate 
TB after administering anti -TNF -α anti-
bodies.3
The currently available anti -TNF -α drugs 
are adalimumab, etanercept and infliximab. 
These three drugs have been approved for 
use in RA, AS, PsA and psoriasis. In addi-
tion, etanercept has also been approved for 
use in juvenile idiopathic arthritis and inf-
liximab and adalimumab for use in Crohn’s 
disease.
Because of its greater epidemiological im-
pact, as compared to other IJDs, RA has 
been considered a model for introducing 
new biotechnology derived drugs that inter-
fere with the immune system.4,5 RA affects 
around 1% of the world population and 
might have a very aggressive course, leading 
to disability, increased co -morbidity and 
mortality.6,7 For this reason, the use of dis-
ease modifying anti -rheumatic drugs – 
DMARDs – should be started as early as 
possible and methotrexate (MTX) is the 
first treatment option for this therapeutic 
strategy. However, in cases where MTX is 
contra -indicated or where it is impossible to 
use an adequate dose due to intolerance or 
toxicity, other immune modulating drugs 
may be used, such as leflunomide, cy-
closporine and sulphasalazine. In patients 
who continue to present active disease, de-
spite of the use of MTX at the maximum 
tolerated dose, alternative therapeutic mea-
sures should be taken, specifically the intro-
duction of an anti -TNF -α drug. This ap-
proach is supported by international 
recommendations8 and by the guidelines 
for using biologic agents in RA therapy9 
published by the Rheumatoid Arthritis 
Study Group (Grupo de Estudos de Artrite 
Reumatóide– GEAR) of the Portuguese So-
ciety of Rheumatology (SPR). The Portu-
guese experience on the use of biologic ther-
apies in the treatment of RA has been 
recently reviewed by the SPR.10 The SPR 
also sponsored guidelines for initiating bio-
logic therapy in AS11 and published the Por-
tuguese experience on the use of biologic 
therapies in the treatment of this disease.12 
There are no specific guidelines on when to 
start biologic therapy in PsA, but in general, 
polyarticular forms similar to RA are treated 
according to the SPR recommendations for 
RA, and cases that are predominantly axial 
are treated according to the SPR recom-
mendations for AS.
Keeping patients on anti -TNF -α therapy 
depends on documenting its efficacy. The 
three TNF -α antagonists seem to display 
similar clinical effectiveness in the diseases 
mentioned above. However, there are differ-
ences from the molecular point of view, and 
the mechanisms whereby each drug acts are 
not entirely equal. Etanercept is a dimeric 
fusion protein consisting of the extracellular 
ligand of the p75 TNF receptor combined 
with the Fc portion of human IgG1. It 
forms stable bonds with the soluble trimeric 
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forms of TNF -α and TNF -α (lymphotox-
in), keeping them from interacting with 
their respective receptors. It also interacts 
with monomeric TNF -α and with trans-
-membrane TNF -α, but in this case the af-
finity is low and has a transient effect (90% 
of trans -membrane TNF -α is released from 
the etanercept binding within 10 minutes). 
Etanercept is administered at a dose of 25 
mg twice weekly or 50 mg once weekly, as a 
subcutaneous (SC) injection. Etanercept 
may be used for RA treatment as monother-
apy or in association with MTX (in this case 
the literature reports enhanced effective-
ness13).14 It has been approved as monother-
apy against AS and PsA14, but is generally 
used together with MTX to treat PsA. Inf-
liximab is a chimeric monoclonal antibody 
with a high affinity and specificity for TNF-
-α, forming stable complexes with mono-
meric and trimeric TNF -α, and with trans-
-membrane TNF -α. Infliximab has no 
affinity for TNF -α(lymphotoxin). The 
binding to trans -membrane TNF -α induces 
cell lyses, mediated by complement depen-
dant cytotoxicity or antibody dependent 
cellular cytotoxicity. It can also induce apop-
tosis by mechanisms that are not fully un-
derstood, but known to involve the caspas-
es.15 These cellular effects lead to a reduction 
in the number of TNF -α producing cells 
(monocytes and CD4 and CD8 lympho-
cytes), that is not observed with etaner-
cept.16 Infliximab is administered intrave-
nously in doses that vary according to the 
disease and clinical response.17 In RA it is 
used in association with MTX, usually in 
doses of 3 mg/kg every 8 weeks.17 In PsA it 
is used in association with MTX, usually in 
doses of 5 mg/kg every 8 weeks.17 In AS, it 
is used as monotherapy in doses of 5 mg/kg 
every 6 weeks.17 Adalimumab is a human 
recombinant monoclonal IgG1 antibody, 
with a mechanism of action similar to inf-
liximab. It is administered subcutaneously 
at 40 mg doses every other week.18 Adali-
mumab may be used for the treatment of 
RA as monotherapy or in association with 
MTX18 (in this case the literature reports 
enhanced effectiveness).19 Adalimumab has 
been approved for use as monotherapy18 in 
PsA and AS. 
In the US, where the annual incidence of 
TB is 6.2 cases per 100,000 inhabitants, the 
incidence of TB in patients treated with in-
fliximab is 54 per 100,000 and, with etaner-
cept, 28 per 100,000. This difference may 
merely be due to the different risk of reacti-
vating TB in the populations exposed to 
these two anti -TNF -α drugs.20 However, 
the different mechanism of action could 
also explain the lower risk of TB reactiva-
tion in patients treated with etanercept. In 
fact, the above described effect of anti -TNF-
-α monoclonal antibodies on the cells ex-
pressing TNF -α, and their ability to irre-
versibly inhibit receptor p75 and p55 
signaling, constitutes an hypothetical reason 
for a reduced preservation of granuloma in-
tegrity during continuous therapy with inf-
liximab and adalimumab.21
Since 2002, specific guidelines for screening 
candidates to anti -TNF -α therapy for ac-
tive and latent TB9 have been followed. 
However, in spite of this, there have been 
cases of TB in this group of patients, espe-
cially among those on monoclonal antibody 
therapy (infliximab and adalimumab). This 
has been observed in Portugal in a study 
performed by the SPR.22
The incidence of TB in the general Portu-
guese population (29.4/100,000 inhabit-
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ants in 2006)23 is much higher than the rate 
in the US and in most European countries. 
This fact requires that the international rec-
ommendations concerning screening and 
treating these patients for TB should be 
adapted to the Portuguese reality. 
For these reasons, SPR’s GEAR and the Tu-
berculosis Committee (TC) of the Portu-
guese Pulmonology Society (SPP) have 
elaborated recommendations for the diag-
nosis and treatment of LTBI and ATB in 
IJD patients treated with anti -TNF -α and 
other immunosuppressant drugs. 
The main objective of these recommenda-
tions is to contribute for the reduction of 
the number of cases of reactivated TB and 
new TB infections in patients who are can-
didates for treatment with TNF -α antago-
nists in Portugal. An additional objective is 
also to standardize the procedures used to 
screen and prevent tuberculosis in the initial 
assessment of IJD patients, preferably be-
fore the onset of any immunosuppressant 
therapy.
A group of experts was appointed by SPR’s 
GEAR and SPP’s TC to develop these rec-
ommendations. The group made an exten-
sive review of the literature using the 
PubMed/Medline search engine and the fol-
lowing keywords: tuberculosis and TNF -α 
antagonists – 199 publications; tuberculosis 
and infliximab – 184 publications, tubercu-
losis and adalimumab – 48 publications, 
tuberculosis and etanercept – 89 publica-
tions, isoniazid and methotrexate – 26 pub-
lications. In addition, the group reviewed 
the following information: TB in patients 
undergoing anti -TNF therapy22, data on 
TB23 published by the General Directorate 
of Health (“Direcção Geral de Saúde”), na-
tional standards for the treatment of LTBI24 
and the international recommendations for 
screening and preventing TB in candidates 
for TNF -α antagonists therapy.25 -28 The rec-
ommendations were also based on the op-
erational capacity of the Pulmonology Di-
agnostic Centers (Centros de Diagnóstico 
Pneumológico– CDP) and the Pulmonolo-
gy and Rheumatology Departments. When 
the recommendations were ready, but be-
fore the final document was concluded, they 
were submitted to the review of two Span-
ish specialists responsible for the evaluation 
of the effectiveness of the Spanish recom-
mendations to prevent reactivation of latent 
tuberculosis infection in patients treated 
with tumor necrosis factor antagonists (LC 
and JGR)26, and also to a specialist in infec-
tious diseases experienced in the treatment 
of tuberculosis (Dr. Germano do Carmo). 
The recommendations were presented and 
submitted to a public debate at a round ta-
ble organized specifically for this purpose in 
the Portuguese Rheumatology Congress 
(April, 2006) and during a national meeting 
in the World TB Day (March, 2006). 
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Fig. 1 – Patients with IJD – initial assessment. Decision to treat LTBI/ATB. If criteria 1, 2 and 3 are negative, do not 
treat for LTBI/ATB
IJD: Infl ammatory Joint Disease; TB: Tuberculosis; LTBI: Latent tuberculosis infection; ATB: Active tuberculosis; AFB: Acid -fast bacilli; TST: 
Tuberculin skin test
Recomendações para o diagnóstico e tratamento das tuberculoses latente e activa 
nas doenças inflamatórias articulares candidatas a terapêutica com fármacos 
inibidores do factor de necrose tumoral alfa. Revisão de Março de 2008
João Eurico Fonseca, Helena Lucas, Helena Canhão, Raquel Duarte, Maria José Santos, Miguel Villar, Augusto Faustino, Elena Raymundo
R e v i s t a  P o r t u g u e s a  d e  P n e u m o l o g i a 277
Vol XIV  N.º 2  Março/Abril  2008
Fig. 2. IJD patients who are candidates for TNF -α treatment decision to treat LTBI/ATB. If criteria 1, 2 and 3 are negative, 
do not treat for LTBI/ATB
IJD: Infl ammatory Joint Disease; TB: Tuberculosis; LTBI: Latent tuberculosis; ATB: Active tuberculosis; TST: Tuberculin skin test; AFB: 
Acid -fast bacilli
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In June 2006, the initial draft version of the 
recommendations was placed on the SPR 
Internet website to enable further public de-
bate. The recommendations included the 
suggestions and criticisms received as part 
of this final public debate process.
The first version of these guidelines was 
published in September 200629,30 and placed 
on the General Directorate of Health Inter-
net website in December 2006. This first 
review was based on the clinical experience 
obtained on the use of these recommenda-
tions during 2007 and on new data recently 
published.
The applicability, effectiveness and safety of 
these recommendations will be regularly re-
viewed by the Sponsoring Societies (SPR 
and SPP); the recommendations will be re-
viewed whenever warranted by new data or 
evidence.
Recommendations
Due to the compromised immunity ob-
served in RA and other IJD patients, as a 
consequence of the physiopathology of the 
disease itself and of immunosuppressant 
therapies,26 rheumatologists should screen 
for ATB and LTBI (Fig. 1) as early as pos-
sible, preferably at the moment of the diag-
nosis of an IJD. The objective is to obtain 
an evaluation of each patient before any 
immunosuppressant therapy is started. At 
this time the diagnostic accuracy of the tu-
berculin skin test is similar to the one ob-
tained in the general population, thus en-
abling the treatment to be focused on the 
individuals with the highest probability of 
having LTBI. However, even if patients 
have been screened at the onset of disease, 
screening should be repeated before start-
ing treatment with anti -TNF -α. If the ini-
tial assessment was negative, the second 
screening will recognize any LTBI or ATB 
that may have occurred in the meantime. 
In individuals that have been treated for 
LTBI before, this second screening will 
identify any possible ATB. If correctly per-
formed, LTBI treatment should only be 
done once in the lifetime.
These patients should be assessed based on 
their clinical history, focusing on TB risk 
factors, as well as complementary tests to 
detect ATB or LTBI.
The following situations should be referred 
to a CDP:
Patients with indication for treatment of 
LTBI or ATB;
Patients with symptoms suggesting ATB; 
Patients at high risk for TB; 
Patients with Gohn’s complex or healed le-
sions on chest X -rays and a history of 
untreated TB; 
Patients with a positive tuberculin skin test, 
All patients with IJD patients who are anti-
-TNF -α candidates and are already im-
munossuppressed; 
The tuberculin skin test should be per-
formed and interpreted in a CDP, whenever 
possible.
When treatment for tuberculosis (LTBI or 
ATB) is indicated, this should preferably be 
completed before starting anti -TNF -α. 
However, If the IJD activity justifies the 
need for immediate treatment, anti -TNF-
-αtherapy can be started two months after 
the beginning of antituberculous therapy in 
the case of ATB, and one month after the 
beginning of antituberculous therapy in the 
case of LTBI.25, 31, 32 
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Clinical history
a) Symptoms suggestive of ATB → if yes, 
refer to CDP
b) Check personal history for TB risk fac-
tors → if yes, refer to CDP
 i. previous TB
 ii. recent immigrants coming from coun-
tries with a high incidence of TB
 iii. recent contact with infectious patients
 iv. health care professionals
 v. IV drug users
 vi. diabetes, HIV infection, leukemias, 
lymphomas, head, neck or lung cancer
Complementary tests to be done
c) Chest X -Ray that can be:
 i. Normal
 ii. Abnormal:
1. Gohn’s complex → treat for LTBI, 
refer to CDP
2. Fibrotic lesions
a. Past history of properly treat-
ed TB → the decision will 
depend on other proce-
dures
b. Past history of untreated or 
incorrectly or incompletely 
treated TB → exclude ATB 
→ treat for LTBI, refer to 
CDP
3. Active lesions → confirm ATB diag-
nosis → treat for ATB, refer to CDP
d) In the presence of symptoms or X -Ray 
findings suggestive of active tuberculosis, 
check for the presence of Mycobacterium tu-
berculosis (microscopic examination and 
culture of sputum and, if positive, perform 
drug susceptibility tests). 
e) Tuberculin skin test (TST) should be in-
terpreted as follows:
 i. < 5 mm – negative → repeat TST on 
the other forearm within the next 7 
to 14 days. If the second test is posi-
tive (≥ 5 mm), only this last result 
should be used.
 ii. ≥5 mm – positive in any patient who 
is about to start anti -TNF -α treat-
ment or in the initial assessment of 
any IJD patient who fulfill the criteria 
for an immunossuppressed patient.
 iii. ≥ 10 mm – positive in the initial as-
sessment of any IJD disease and in 
patients who do not meet the criteria 
for an immunossuppressed patient.
Procedure following tuberculin test
 -if positive (ii and iii) → treat for LTBI (ex-
cept if a correct treatment was performed in 
the past), refer to CDP
– if negative:
a) Patient not previously exposed to immu-
nosuppressive drugs → initiate anti -TNF -α
b) Immunossuppressed patient → treat as 
LTBI, refer to CDP. This decision should be 
taken on an individual basis, after a benefit / 
risk assessment, taking into account the age of 
the patient, ethanol consumption, previous he-
patic diseases and the evaluation of LTBI risk.
Notes
• Immunossuppressed patients are those 
with established IJD, treated with ster-
oids (prednisolone in doses higher than 
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10 mg/day) and/or with immunosup-
pressant drugs such as MTX, cy-
closporine, azathioprine, leflunomide 
or cyclophosphamide, regardless of the 
dose. 
• For immunossuppressed patients, a 
negative tuberculin skin test does not 
exclude TB. For this reason, if the tu-
berculin test is conducted in an immu-
nossuppressed phase, the patient should 
be treated for LTBI before starting anti-
-TNF -α therapy, even if the test is neg-
ative. This decision should be taken on 
an individual basis, after a benefit / risk 
assessment, taking into account the age 
of the patient, ethanol consumption, 
previous hepatic diseases and the evalu-
ation of LTBI risk.
• Some authors33 suggest that tuberculin 
skin test should not be conducted on 
immunossuppressed patients who are 
candidates for treatment with TNF -α 
antagonists, given the decision to treat 
them for LTBI regardless of the result 
of the tuberculin skin test. These rec-
ommendations defend the tuberculin 
skin test, as this information may be 
useful in the future to determine the 
sensitivity and specificity of the tuber-
culin skin test in such patients, and 
may help to assess the impact of LTBI 
treatment based on the tuberculin skin 
test result.
• The threshold for considering a positive 
tuberculin skin test was reduced from 
10mm to 5mm in patients who will start 
therapy with TNF -α antagonists, even 
in the absence of depressed immunity 
criteria, because of the high risk of devel-
oping serious forms of TB associated 
with the use of these drugs.
Treatment regimens for latent tubercu-
losis
a) Isoniazid for 6 months (6H) – 60% effi-
cacy. Level of evidence: A31
b) Isoniazid for 9 months (9H) – 70% effi-
cacy. Level of evidence: A26
c) Isoniazid and Rifampicin for 3 months 
(3HR) – 50% efficacy. Level of evidence: A31
d) Isoniazid, Rifampicin and Pyrazinamide 
for 2 months (2HRZ) – efficacy study cur-
rently underway. Level of evidence: D34
Treatment regimens for active tuberculosis
e) Isoniazid, Rifampicin, Pyrazinamide and 
Ethambutol for 2 months, followed by Iso-
niazid and Rifampicin for 4 months.35,36 
f ) Other regimens may be proposed in spe-
cific cases (co -morbidities, such as liver or 
kidney failure, or if drug susceptibility test-
ing indicates resistance to some of the first-
-line drugs).
Comments
1. Patients should be screened and treated 
for LTBI or ATB when an IJD is first diag-
nosed and when the patient is a candidate 
for starting anti -TNF -α therapy.
2. Although prior screening is mandatory 
for all patients treated with TNF -α an-
tagonists, none of the LTBI treatment 
regimens is 100% effective. In addition, 
patients contact with hospital environ-
ments, where there is a higher risk of con-
tacting with TB patients, increasing the 
risk of new infections. For these reasons, 
patients should be carefully monitored 
for TB symptoms throughout the period 
they receive anti -TNF -α drugs and for six 
months after the drugs are discontinued. 
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This clinical vigilance should be comple-
mented, whenever necessary, by X -Rays 
and other suitable complementary diag-
nostic tests.25
3. Therapy for ATB should be administered 
under direct observation (DOT).
4. For TST it should be used 2 units of 
RT23 Tuberculin.
5. There are new tests to diagnose LTBI, 
such as γ -interferon quantification; their 
usefulness in immunossuppressed IJD pa-
tients is currently being assessed. 
6. Treatment for ATB and LTBI must be 
done under the care of a TB specialist, who 
will also address all diagnostic or therapeu-
tic questions.
7. There is toxicity, especially liver toxicity, 
associated with LTBI therapy. The risk of 
liver toxicity increases with age. There is 
little data available on the risk of liver tox-
icity in IJD patients treated with DMARDs 
combined with anti -tuberculous drugs.37,38 
Patients should be carefully watched by a 
CDP specialist, both clinically and with 
laboratory tests, using the prevailing guide-
lines.24
8. In non -immunossuppressed patients, the 
risk of LTBI evolving to ATB is 10% over a 
patient’s lifetime24, 39, 40. Treatment for LTBI 
reduces this risk to about 0.5%.39,40
9. In immunossuppressed patients, the risk 
of LTBI evolving to ATB is 8 to 10% per 
year.41 In these patients, ATB may present 
atypically (making the diagnosis more dif-
ficult and often delayed) and it is generally 
more serious and associated with higher 
mortality rates.
10. LTBI therapy effect lasts for over 20 
years. In fact, some authors even admit 
that the effect lasts for the patient’s life-
time41. Because of this, patients are treated 
for LTBI only once. LTBI treatment plans 
and duration are identical for all patients, 
regardless of being immunossuppressed or 
not.
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